| human | Q5 |
| P106 | occupation | author | Q482980 |
| Q39845371 | A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates |
| Q47558450 | Absence of HIV-1 drug resistance mutations supports the use of dolutegravir in Uganda. |
| Q38854117 | Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa |
| Q98775305 | Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda |
| Q38866266 | Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children |
| Q39914312 | Calculating HIV-1 infectious titre using a virtual TCID(50) method |
| Q89471761 | Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda |
| Q35230246 | Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D. |
| Q101573301 | Deep gene sequence cluster analyses of multi-virus infected mucosal tissue reveal enhanced transmission of acute HIV-1 |
| Q35880435 | Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women |
| Q61445231 | First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda |
| Q37062207 | HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda |
| Q33669836 | HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa. |
| Q33344364 | HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle? |
| Q38869669 | HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study |
| Q47551736 | Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection. |
| Q35187981 | Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe |
| Q37617869 | Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay |
| Q37604707 | Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa |
| Q36933330 | Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. |
| Q38791126 | Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial |
| Q38855053 | Once vs twice-daily abacavir and lamivudine in African children |
| Q38858252 | Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. |
| Q38853002 | Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance |
| Q46499496 | Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries |
| Q38865733 | Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy |
| Q42104990 | Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication |
| Q30425595 | The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART. |
| Q38881548 | Towards a better understanding of exclusive breastfeeding in the era of HIV/AIDS: a study of prevalence and factors associated with exclusive breastfeeding from birth, in Rakai,Uganda |
| Q35827900 | Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period |
| Q34523909 | Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda |
Search more.